Bifidobacterium bifidum
Immune modulating Bifidobacterium
strain with high adhesion activity.
- Isolated from the feces of healthy breast-feeding infants
- US FDA GRAS Notification GRN No. 814
- Deposited at the Korean Culture Center of Microbiology as KCCM 80046
-
KR Patented / Complete genomic sequenced
(GenBank no. CP001361)
Bio-functional
effects
Bifidobacterium bifidum BGN4 was found to produce chiroinositol-containing polysaccharide (BB-pol), which showed anti-tumor activity on human colon cancer cell lines.
Global
Notifications
USA
NDI
(New Dietary Ingredient) approved by FDA [NDI 1079]
USA
GRAS
(Generally Recognized As Safe) approved by FDA [GRN 000814]
KOREA
1. Patented strain probiotics.
KOREA
2. Patented strain probiotics.
KOREA
Halal certificate recognized by Korea Muslim Federation Halal Committee.
Europe
Recognized by the European Food Safety Authority with Qualified Presumption of Safety (QPS)
Australia
Included in “Approved Terminology for Medicines Section – Biological List” by TGA
Canada
Can be used as Medicinal Ingredients of Natural Health Product
CHINA
Recognized by CFDA used in food
Featured in
book chapters
B. bifidum BGN4, originated from a breast fed infant, is well documented regarding clinical evidence for its health promoting effects by various researchers of universities and hospitals and have been featured in the international textbooks of microbiology.
The Probiotics Revolution
Glycoside Hydrolases—
Advances in Research and
Application: 2013 Edition
The Microbiota in
Gastrointestinal
Pathophysiology
The Bifidobacteria and
Related Organisms
Aptamers
Handbook of Prebiotics and
Probiotics Ingredients
Global
application
More
References
Certificate
- • Non-GMO
- • BSE-free
- • TSE-free
- • No Allergen
- • Halal Certi
Packaging
- • 1kg / pack
- • 10pack/box
Safety
- • US FDA GRAS approved
- • US FDA NDI approved
- • Whole Genome Sequencing
- • 30 years without side effect
Storage Condition
Be kept in an airtight container
and stored at a temperature not
exceeding 8℃
